Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
thyroid eye disease
Pharma
Roche's Enspryng muscles in on Tepezza's TED turf
Some six years after scoring an initial FDA nod, Roche’s IL-6 receptor inhibitor Enspryng is muscling up to Amgen's Tepezza in a key eye disease arena.
Fraiser Kansteiner
Oct 16, 2026 9:26am
Viridian set for 1-on-1 vs. Amgen after FDA approval of Lumvoa
Jun 29, 2026 8:32am
On-body injected version of Amgen's Tepezza measures up to IV
Apr 6, 2026 9:43am
Argenx cans Vyvgart trials in thyroid eye disease over futility
Dec 15, 2025 10:00am
Improved access helps Amgen's Tepezza to a sales increase
Aug 7, 2024 8:35am
Amgen lays out plan to boost sales of newly acquired Tepezza
Oct 31, 2023 11:29am
